ClofiliumAlternative Names: LY 150378
Latest Information Update: 01 Aug 2002
At a glance
- Originator Eli Lilly
- Developer Eli Lilly; Nonindustrial source
- Class Class III antiarrhythmics
- Mechanism of Action Potassium channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Arrhythmias; Atrial fibrillation